Nomograms for Predicting Overall Survival and Cancer-Specific Survival of Patients With Renal Cell Carcinoma and Venous Tumor Thrombus: A Population-Based Study

Lin Yang† and Bin Fu* 

Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, China

Background: To provide better prognostic information for patients with renal cell carcinoma (RCC) combined with venous tumor thrombus (VTT). In turn, guide patients’ families and doctors to formulate plans for follow-up treatment and follow-up. We developed nomograms to predict cancer-specific survival (CSS) and overall survival (OS).

Methods: A total of 2961 cases were included in this study. Through univariate and multivariate Cox proportional hazard regression analysis, independent risk factors affecting CSS and OS were screened out, and then a nomogram was drawn based on the screened variables.

Results: Independent risk factors affecting CSS include: tumor size (HR = 1.05), histology (HR = 1.75), grade (HR = 1.94), N staging (HR = 2.06), and M staging (HR = 2.87). The median survival time for CSS was 106 months. Independent risk factors for OS include age (HR = 1.60), tumor size (HR = 1.04), histology (HR = 1.60), grade (HR = 1.68), N staging (HR = 1.99), M staging (HR = 2.45). The median survival time for OS is 67 months.

Conclusions: The nomogram based on independent risk factors affecting CSS and OS can well predict the prognosis of renal cell carcinoma with venous tumor thrombus.

Keywords: renal cell carcinoma, venous tumor thrombus, cancer-specific survival, overall survival, nomogram

BACKGROUND

Globally, renal cell carcinoma is the 9th most common cancer in men and the 14th most common cancer in women worldwide (1). Approximately 4%–10% of cases were diagnosed with venous tumor thrombus at initial diagnosis (2), and nearly one-third of these patients have concurrent metastatic disease. Although venous system involvement is a late manifestation of the disease, radical nephrectomy with tumor thrombus removal remains the standard treatment for disease control (3).
A meta-analysis pointed out that the 5-year cancer-specific survival (CSS) after surgery was only 25%–53% for these cases (4), which is not optimistic compared with the postoperative survival rate of localized renal cell carcinoma. To evaluate the prognosis of patients with RCC with VTT, E. Jason Abe (5) developed a Nomogram diagnostic chart for predicting postoperative recurrence of non-metastatic RCC with tumor thrombus, and Ahmed Q. Haddad (6) developed a preoperative multivariable prognostic model for prediction of survival and major complications following surgical resection of RCC with VTT. Most of these studies were from single-center or small cohorts, and there was heterogeneity among the prognostic risk factors proposed by different studies.

To help patients and physicians decide on adjuvant therapy, the type and frequency of follow-up, and to provide patients and their families with useful information about treatment modalities and short-term and long-term outcomes, we developed a nomogram predicting tumor-specific and overall survival based on the SEER database.

**METHODS**

**Patient Population and Data Collection**

The SEER database from National Cancer Institute is the most authoritative source of information about cancer incidence and survival in the United States (https://seer.cancer.gov/), and the SEER database is a public database, so no ethical review is required. We logged in to the SEER*stat 8.4.0 software through the account (22230-Nov2020) obtained by registration to extract the required tumor data. Inclusion criteria for the data: (1) over 18 years old, (2) the primary site of the tumor in the kidney, (3) with venous tumor thrombus, (4) having undergone radical nephrectomy (including minimally invasive and open surgery), (5) cases were diagnosed between 2005 and 2015. Exclusion criteria for data: (1) missing important data, (2) bilateral tumors, (3) postoperative pathology suggests tumors of non-renal origin. According to the inclusion and exclusion criteria, a total of 2,961 eligible cases were screened in this study.

**Variables**

We obtained the following case information from the SEER database: age, race, sex, year of diagnosis, Laterality, CS tumor size (2004–2015), CS extension (2004–2015), histology, grade, N staging (AJCC, 6th ed.), M staging (AJCC, 6th ed.), cause-specific death, vital status, survival months. Because renal cell carcinoma patients over 65 years old have significantly higher Microvascular density than younger (<65 years old) patients. Microvascular density is an important factor affecting the occurrence and development of tumors, so the age of 65 is a key node (7). Age was divided into two groups (≤65 years vs >65 years), the race was divided into white group and other groups, sex included male and female, and year of diagnosis was divided into two groups (2005–2010 vs 2011–2015), tumor Laterality includes left and right. Tumor size was converted to centimeters according to the code, venous tumor thrombus was divided into two groups (under the diaphragm vs above the diaphragm) according to the code (600, 601, 610, 640, 620, 645), histology was divided into clear cell carcinoma group and other groups, tumor nuclear grades include grade I, grade II, grade III, and grade IV, and were divided into two groups (I/II vs III/IV). Tumor without lymph node metastasis was defined as N0, lymph node metastasis was defined as N1.

**TABLE 1 | Clinicopathological features of renal cell carcinoma patients with venous tumor thrombus.**

| Variables                                      | Value (n = 2,961) |
|------------------------------------------------|-------------------|
| Age (years)                                    |                   |
| ≤65                                            | 1,650 (55.7%)     |
| >65                                            | 1,311 (44.3%)     |
| Race                                           |                   |
| White                                          | 2,455 (82.9%)     |
| Others                                         | 506 (17.1%)       |
| Sex                                            |                   |
| Female                                         | 922 (31.1%)       |
| Male                                           | 2,039 (68.9%)     |
| Laterality                                     |                   |
| Left                                           | 1,502 (50.7%)     |
| Right                                          | 1,459 (49.3%)     |
| Tumor size(cm)                                 | 8.78 ± 3.53       |
| Histology                                      |                   |
| Clear cell adenocarcinoma                      | 2,728 (92.1%)     |
| Others                                         | 233 (7.9%)        |
| Grade                                          |                   |
| I/II                                           | 868 (29.3%)       |
| III/IV                                         | 2,093 (70.7%)     |
| N stage                                        |                   |
| N0                                             | 2,555 (86.3%)     |
| N1                                             | 406 (13.7%)       |
| M stage                                        |                   |
| M0                                             | 2,290 (77.3%)     |
| M1                                             | 671 (22.7%)       |
| Violation of adrenal glands                    |                   |
| NO                                             | 2,930 (99.0%)     |
| YES                                            | 31 (1.0%)         |
| Venous tumor thrombus                          |                   |
| Below the diaphragm                            | 2,857 (96.5%)     |
| Above the diaphragm                            | 104 (3.5%)        |
| Cancer-specific survival                       |                   |
| Alive                                          | 1,677 (56.6%)     |
| Dead                                           | 1,284 (43.4%)     |
| Overall survival                               |                   |
| Alive                                          | 1,288 (43.5%)     |
| Dead                                           | 1,673 (56.5%)     |
| Survival months                                | 56.7 ± 42.05      |

Continuous variables were presented as means ± standard deviations and categorical variables as frequency (percentage).
no distant metastasis was defined as M0, and distant metastasis was defined as M1. Cause-specific death includes alive (or death of other cause) and dead (attributable to this cancer), the latter being defined as the primary outcome of cancer-specific survival (CSS). Vital status includes alive and dead, the latter being defined as the primary outcome of overall survival (OS). Survival months refer to how long a patient survives during the follow-up period.

**Statistical Analysis**

Continuous variables were presented as means ± standard deviations and categorical variables as frequency (percentage). Clinical variables associated with CSS and OS were assessed based on clinical importance, scientific knowledge, and predictors identified in previously published articles (8–10). Univariable and multivariable Cox proportional hazards regression model analyses were performed for CSS and OS. Univariate predictive variables with $p<0.05$ were applied to multivariate analyses to identify the independent prognostic factors. Hazard ratios (HRs) were presented with their 95% CIs. Then, a nomogram model was established using the independent risk factors screened out by the multivariable Cox proportional hazards regression model (rms in R, version 4.1.3; http://www.r-project.org). In addition, computing the C

| Variable                                      | Univariable |          | Multivariable |          |
|-----------------------------------------------|-------------|----------|--------------|----------|
|                                      | HR | 95% CI  | $p$-value | HR | 95% CI  | $p$-value |
| **Factors Selected**                        |    |          |           |    |          |           |
| Tumor size (cm)                              | 1.11 | 1.09 | 1.12 | <0.001 | 1.05 | 1.04 | 1.07 | <0.001 |
| Histology                                    |    |          |           |    |          |           |
| Clear cell adenocarcinoma                    | 2.41 | 2.03 | 2.85 | <0.001 | 1.75 | 1.47 | 2.08 | <0.001 |
| Others                                       |    |          |           |    |          |           |
| Grade                                        |    |          |           |    |          |           |
| I/II                                         | 2.80 | 2.42 | 3.23 | <0.001 | 1.94 | 1.67 | 2.26 | <0.001 |
| III/IV                                       |    |          |           |    |          |           |
| N stage                                      |    |          |           |    |          |           |
| N0                                           | 3.99 | 3.51 | 4.43 | <0.001 | 2.06 | 1.79 | 2.36 | <0.001 |
| N1                                           |    |          |           |    |          |           |
| M stage                                      |    |          |           |    |          |           |
| M0                                           | 4.19 | 3.74 | 4.69 | <0.001 | 2.87 | 2.54 | 3.25 | <0.001 |
| M1                                           |    |          |           |    |          |           |
| **Factors Not Selected**                     |    |          |           |    |          |           |
| Age                                          |    |          |           |    |          |           |
| ≤65 years                                    | 1.07 | 0.96 | 1.19 | 0.24  |    |          |           |
| >65 years                                    |    |          |           |    |          |           |
| Race                                         |    |          |           |    |          |           |
| White                                        | 1.09 | 0.95 | 1.26 | 0.23  |    |          |           |
| Others                                       |    |          |           |    |          |           |
| Sex                                          |    |          |           |    |          |           |
| Female                                       | 0.99 | 0.88 | 1.11 | 0.81  |    |          |           |
| Male                                         |    |          |           |    |          |           |
| Laterality                                   |    |          |           |    |          |           |
| Left                                         | 0.90 | 0.81 | 1.01 | 0.07  |    |          |           |
| Right                                        |    |          |           |    |          |           |
| Violation of adrenal glands                  |    |          |           |    |          |           |
| N0                                           | 3.20 | 2.15 | 4.75 | <0.001 | 0.97 | 0.65 | 1.45 | 0.88  |
| YES                                          |    |          |           |    |          |           |
| Venous tumor thrombus                        |    |          |           |    |          |           |
| Under the diaphragm                          | 1.62 | 1.25 | 2.11 | <0.001 | 1.17 | 0.89 | 1.53 | 0.26  |
| Above the diaphragm                          |    |          |           |    |          |           |

HR, hazard ratio; CI, confidence interval.
statistic estimates the probability that the predicted outcome agrees with the observed outcome. Bootstrap validation (1,000 resamples) was performed and nomogram performance was determined using a calibration plot of observed versus predicted probabilities. Finally, we drew Kaplan-Meier curves over the tertiles of patients stratified according to the nomogram prediction scores in the dataset to further assess calibration, and differences were examined using the log-rank test. Statistical analyses were performed with software programs (R, version 4.1.3; http://www.r-project.org). All tests were 2-sided, and p < 0.05 was considered statistically significant.

RESULTS

In this study, a total of 2,961 patients with renal cell carcinoma with venous tumor thrombus were included. The clinicopathological characteristics of our study cohort are shown in Table 1. 44.3% of the cases in the cohort were older (>65 years) and mostly white (82.9%). Males (68.9%) accounted for the majority of these patients. The average size of the tumors was 8.78 cm (±3.53 cm), and about half of them were located on the left side (50.7%). The tumor tissues were dominated by clear cells (92.1%), and most of them belonged to grade III/IV (70.7%). Among these cases, 13.7% had lymph

| Variable                                      | Univariable                  | Multivariable                  |
|-----------------------------------------------|------------------------------|--------------------------------|
|                                               | HR   | 95% CI | p-value | HR   | 95% CI | p-value |
| Factors Selected                              |      |        |         |      |        |         |
| Age                                           |      |        |         |      |        |         |
| ≤65 years                                     | 1 [Reference]                | 1.35   | 1.23    | 1.49 | <0.001 | 1.60   | 1.45    | 1.77 | <0.001 |
| >65 years                                     | 1.07 | 1.06   | 1.09    | <0.001 | 1.04 | 1.03   | 1.05    | <0.001 |
| Tumor size (cm)                               |      |        |         |      |        |         |
| Others                                        | 2.16 | 1.85   | 2.16    | <0.001 | 1.60 | 1.37   | 1.88    | <0.001 |
| Histology                                     |      |        |         |      |        |         |
| Clear cell adenocarcinoma                     | 1 [Reference]                | 2.15   | 1.91    | 2.42 | <0.001 | 1.68   | 1.48    | 1.89 | <0.001 |
| Others                                        | 1.11 | 0.98   | 1.26    | 0.10  |      |        |         |        |
| Grade                                         |      |        |         |      |        |         |
| I/II                                          |      |        |         |      |        |         |
| III/IV                                        | 3.23 | 2.86   | 3.64    | <0.001 | 1.99 | 1.74   | 2.26    | <0.001 |
| N stage                                       |      |        |         |      |        |         |
| N0                                            |      |        |         |      |        |         |
| N1                                            | 3.22 | 2.90   | 3.57    | <0.001 | 2.45 | 2.19   | 2.74    | <0.001 |
| M stage                                       |      |        |         |      |        |         |
| M0                                            |      |        |         |      |        |         |
| M1                                            | 1.11 | 0.98   | 1.26    | 0.10  |      |        |         |        |
| Factors Not Selected                          |      |        |         |      |        |         |
| Race                                          |      |        |         |      |        |         |
| White                                         |      |        |         |      |        |         |
| Others                                        | 1.11 | 0.98   | 1.26    | 0.10  |      |        |         |        |
| Sex                                           |      |        |         |      |        |         |
| Female                                        |      |        |         |      |        |         |
| Male                                          | 0.97 | 0.87   | 1.07    | 0.50  |      |        |         |        |
| Laterality                                    |      |        |         |      |        |         |
| Left                                          |      |        |         |      |        |         |
| Right                                         | 0.96 | 0.88   | 1.06    | 0.45  |      |        |         |        |
| Violation of adrenal glands                   |      |        |         |      |        |         |
| N0                                            | 1 [Reference]                | 2.53   | 1.71    | 3.76 | <0.001 | 0.83   | 0.55    | 1.24 | 0.35  |
| YES                                           | 1.58 | 1.25   | 2.00    | <0.001 | 1.23 | 0.97   | 1.56    | 0.09  |

HR, hazard ratio; CI, confidence interval.
FIGURE 1 | Nomogram for predicting postoperative CSS in patients with renal cell carcinoma complicated with venous tumor thrombus.

FIGURE 2 | Nomogram for predicting postoperative OS in patients with renal cell carcinoma complicated with venous tumor thrombus.
node metastasis (N1), 22.7% had distant metastasis (M1), and 1% had an adrenal invasion. The venous tumor thrombus of most tumors was located below the diaphragm (96.5%). At the end of follow-up, 43.4% of patients died from renal cell carcinoma and 56.5% from all causes, with a mean survival time of 56.7 months (±42.05 months). The CSS ratios at 1, 3 and 5 years were 85.6%, 70.1% and 60.2%. The OS rates at 1, 3, and 5 years were 83.3%, 65.4%, and 52.8%. Median survival for CSS was 106 months (95% CI, 91–123 months) and median survival for OS was 67 months (95%, 62–73 months).

Shown in Tables 2, 3 are cox proportional hazards regression models for variables versus CSS, OS. First, univariate regression analysis was performed to screen out variables with \( p < 0.05 \), and then they were included in multivariate regression analysis. Finally, the following independent risk factors for CSS were obtained: tumor size (HR: 1.05, 95% CI, 1.04–1.07, \( p < 0.001 \)), histology (HR:1.75, 95% CI, 1.47–2.08, \( p < 0.001 \)), grade (HR:1.94, 95% CI, 1.67–2.26, \( p < 0.001 \)), \( N \)_stage (HR:2.06, 95% CI, 1.79–2.36, \( p < 0.001 \)), \( M \)_stage (HR:2.87, 95% CI, 2.54–3.25, \( p < 0.001 \)). The following were independent risk factors for OS: age (HR: 1.60, 95% CI, 1.45–1.77, \( p < 0.001 \)), tumor size (HR:1.04, 95% CI, 1.03–1.05, \( p < 0.001 \)), histology (HR:1.60, 95% CI, 1.37–1.88, \( p < 0.001 \)), grade (HR:1.68, 95% CI, 1.48–1.89, \( p < 0.001 \)), \( N \)_stage (HR:1.99, 95% CI, 1.74–2.26, \( p < 0.001 \)), \( M \)_stage (HR:2.45, 95% CI, 2.19–2.74, \( p < 0.001 \)).

Nomograms predicting CSS and OS at 1, 3, and 5 years after surgery in patients with renal cell carcinoma with venous tumor thrombus were shown in Figures 1, 2. The nomogram for predicting CSS was based on several variables: tumor size, histology (clear cell carcinoma or other), grade (I/II or III/IV), \( N \)_stage (N0 or N1), \( M \)_stage (M0 or M1). Likewise, nomograms for predicting OS were based on several variables: age (≤65 or >65 years), tumor size, histology (clear cell carcinoma or other), grade (I/II or III/IV), \( N \)_stage (N0 or N1). As assessed by the nomogram, the higher the cumulative score, the higher the risk of poor prognosis. To verify the predictive accuracy of the nomogram, we calculated each
with the advancement of surgical techniques and instruments, radical nephrectomy combined with tumor thrombus removal has become the standard treatment for patients with renal cell carcinoma combined with venous tumor thrombus (11). Although these patients have achieved a significant survival benefit relative to patients who have not undergone surgery (12), overall, the long-term survival rate of patients with tumor thrombus is still low (13). In recent years, the rapid development of targeted therapy and immunotherapy has brought new hope for some patients. Some studies have reported that some patients with advanced renal cancer or tumor thrombus can benefit from these two treatments (14, 15). Therefore, conducting postoperative risk stratification for patients with RCC is complicated by VTT to guide follow-up and treatment. We screened 2,961 patients based on the SEER database. After univariate and multivariate Cox proportional hazards regression analysis, we obtained five...
**FIGURE 5** | Calibration plot comparing predicted and actual survival probability at 36 months follow-up.  
C-index = 0.75

**FIGURE 6** | Calibration plot comparing predicted and actual survival probability at 36 months follow-up.  
C-index = 0.71
independent risk factors affecting CSS: tumor size, histology, grade, N_stage, M_stage; six affecting OS Independent risk factors: age, tumor size, histology, grade, N_stage, M_stage, and nomograms of CSS and OS were drawn.

Similar results have been reported in other studies, but the risk factors identified by different studies are quite different, and even the conclusions are opposite. According to the seventh edition of the AJCC Cancer Staging Manual (16), tumor size is an important basis for T1 and T2 staging. Brett et al. (17) reported that almost all tumors >7 cm in diameter and a substantial proportion of tumors <7 cm in diameter showed extrarenal spread. This suggests that the larger the tumor diameter, the higher the degree of malignancy. Weixing et al. (18) also noted that smaller tumors had a better prognosis for patients with metastatic renal cell carcinoma who underwent cytoreductive nephrectomy. The same is true of our findings that tumor size is a key factor affecting CSS and OS in patients. Because larger tumors may mean more aggressiveness, this can significantly increase the risk of recurrence and metastasis after surgery, leading to a worse prognosis.

Regarding the effect of histological subtypes on the prognosis of patients with renal cell carcinoma, although most studies agree that the prognosis of clear cell carcinoma is better, there is also heterogeneity between the results of different studies. According to a study by Dharam et al. (19), patients with non-clear cell carcinoma have larger tumor size, higher nuclear grade, more frequent sarcoid differentiation, and more frequent lymph node invasion, which leads to a worse prognosis. Similarly, studies by the International Renal Cell Carcinoma-Venous Thrombus Consortium (8) and Liangyou et al. (20) also suggested that the histological type of non-clear cell carcinoma is an independent risk factor for poor prognosis. However, for patients with tumor thrombosis, the study by Nocera et al. (21) came to different conclusions. The three histologic subtypes, clear cell, papillary, and chromophobe, almost all exhibited poor cancer-specific mortality (CSM) in patients with T3b-T4 RCC, with no clinically meaningful
between-group differences in CSM. Our findings suggest that histological type is an independent risk factor for CSS and OS in patients with tumor thrombus, perhaps because Luigi Nocera’s subgroup did not include patients with stage T3a and M1, resulting in heterogeneity of results, so we still tend to think that histological type is a key factor affecting the prognosis of patients with tumor thrombus. In addition, our study found that in patients with renal cell carcinoma and venous tumor thrombus, most tumors had higher nuclear grades (grade = III/IV: 2,093 (70.7%)). Nuclear grade in renal cell carcinoma has been recognized as a prognostic factor for nearly 100 years (22), and our findings also suggest that nuclear grade is an independent risk factor for CSS and OS in patients. From this, it may be reasonable to infer that a higher nuclear grade may be one of the important reasons for the high invasiveness of venous tumor thrombus and the poor prognosis of patients with tumor thrombus.

It is well known that lymph node metastasis in cancer patients often indicates a more aggressive tumor and a worse prognosis. The same is true of our findings. Patients with venous tumor thrombus with lymph node metastasis have a 2.06-fold increased risk of tumor-specific death (HR = 2.06, \( p < 0.001 \)) and a 1.99-fold increased overall mortality risk (HR = 1.99, \( p < 0.001 \)). Arnav’s (23) study of patients with pathological node-positive renal cell carcinoma found that patients with node-negative stage III had better survival (5-year survival: 61.9%), but node-positive stage III (5-year survival: 22.7%) survival was similar to that of stage IV (5-year survival: 15.6%) RCC patients. They believe that such patients should be further stratified to guide lymph node dissection and subsequent treatment. However, lymph node dissection is not routinely performed during radical nephrectomy because renal tumors metastasize primarily through the hematologic system, and lymph node dissection does not appear to confer any survival benefit for patients (24). On the other hand, a study by the International Renal Cell Carcinoma Venous Thrombus Consortium (25) suggests that lymph node dissection can improve the survival rate of
patients with positive lymph nodes. In conclusion, whether lymph node dissection can bring survival benefits to patients with renal cell carcinoma complicated with venous tumor thrombus still needs higher-quality prospective randomized controlled studies to verify.

Generally speaking, when the tumor progresses to the distant metastatic stage, it means that the disease has reached the terminal stage, and the treatment options at this time are limited. In our study, the presence of distant metastases significantly increased tumor-specific mortality (HR = 2.87) and overall mortality (HR = 2.45). Although studies (26) have shown that Cytoreductive Nephrectomy can improve the OS of patients with renal cell carcinoma with distant metastasis and venous tumor thrombus, the survival rate of these patients is still low. However, with the development of targeted therapy and immunotherapy, new treatment options have been brought to patients with advanced cancer. The finding of a recent randomized controlled trial (27) was surprising in that in patients with metastatic renal cell carcinoma, sunitinib alone was not inferior to sunitinib after nephrectomy. This means that some patients with distant metastases can avoid the risks of surgery and improve their quality of life. So, can patients with renal cell carcinoma combined with venous tumor thrombus benefit from it? We plotted survival curves for 2005–2010 and 2011–2015 and found no improvement in CSS \( p = 0.24 \) and OS \( p = 0.26 \) during these two periods. In other words, the development of targeted drugs did not bring significant survival benefits to patients with tumor thrombi. As shown in Liangyou’s findings (28), postoperative adjuvant sorafenib or sunitinib did not have a survival advantage in patients with non-metastatic renal cell carcinoma and VTT compared with controls. Perhaps, immunotherapy can bring some improvement for these patients. The results of Yoshida’s (29) study showed that patients with RCC and VTT who received immunotherapy all had their tumors shrunk, significantly reducing the risk of surgery. However, whether immunotherapy can improve the long-term survival of such patients still requires prospective studies with larger sample sizes to verify.

Clearly, the higher the level of venous tumor thrombus, the significantly increased perioperative risk (11). However, the effect of the level of venous tumor thrombus on the long-term survival of patients with renal cell carcinoma combined with venous tumor thrombus has been controversial. The International Renal Cell Carcinoma-Venous Thrombosis Consortium (8) believes that the level of tumor thrombus is an independent predictor of survival, and even the T3 stage in the 7th edition of the AJCC Cancer Staging Manual (16) is

based on the level of tumor thrombus. However, our study and those from other centers (9, 10) came to a different conclusion that the level of venous tumor thrombus did not significantly affect the CSS and OS of patients. Perhaps the heterogeneity of the results stems from the differences in the classification of tumor thrombus levels in different studies. To better evaluate the prognosis of these patients, a more detailed classification of the T3 stage should be carried out.

There are some limitations to this study. First, this study is a retrospective study based on the SEER database. In the process of data screening, cases with missing important data were excluded, and there may be errors in the variable coding of the database. These factors may lead to the study of the results deviating from the actual situation. Second, the database did not contain detailed information on patients’ continued adjuvant therapy after surgery, a factor that influenced the findings.

**CONCLUSION**

To sum up, for patients with renal cell carcinoma combined with venous tumor thrombus, tumor size, histology, grade, N_stage, and M_stage are independent risk factors for CSS; age, tumor size, histology, grade, N_stage, and M_stage are the independent risk factors for CSS. Independent risk factors for OS. A nomogram based on these factors can be a good predictor of patient prognosis to guide follow-up and treatment.

**DATA AVAILABILITY STATEMENT**

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://seer.cancer.gov/data/.

**AUTHOR CONTRIBUTIONS**

LY: Data curation, Formal analysis, Writing - original draft, Writing - review & editing. BF: conceptualize research. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was supported by grants from the National Natural Science Foundation of China (81960512).

**REFERENCES**

1. Jonasch E, Gao J, Rathmell WK. Renal cell carcinoma. BMJ. (2014) 349: g4797. doi: 10.1136/bmj.g4797
2. Abbasi A, Johnson TV, Ying K, Baumgarten D, Millner R, Master VA. Duplicated vena cava with tumor thrombus from renal cancer: use of venogram for safer operative planning. Urology. (2012) 79(4):e57–8. doi: 10.1016/j.urology.2011.06.044
3. Pushtka SP, Leibovich BC. Management of inferior vena cava tumor thrombus in locally advanced renal cell carcinoma. Ther Adv Urol. (2015) 7(4):216–29. doi: 10.1177/1756287215576443
4. Gu L, Li H, Wang Z, Wang B, Huang Q, Lyu X, et al. A systematic review and meta-analysis of clinicopathologic factors linked to oncologic outcomes for renal cell carcinoma with tumor thrombus treated by radical nephrectomy with thrombectomy. Cancer Treat Rev. (2018) 69:112–20. doi: 10.1016/j.ctrv.2018.06.014

---

**Yang and Fu**

**Nomogram of Renal Cell Carcinoma**

---

**Frontiers in Surgery | www.frontiersin.org**

---

**2022 | Volume 9 | Article 929885**
5. Abel EJ, Masterson TA, Karam JA, Master VA, Margulis V, Hutchinson R, et al. Predictive nomogram for recurrence following surgery for nonmetastatic renal cell cancer with tumor thrombus. J Urol. (2017) 198(4):810–6. doi: 10.1016/j.juro.2017.04.066

6. Hadj-AO, Lebègue BC, Abel EJ, Luo SJ, Krabbe LM, Thompson RH, et al. Preoperative multivariable prognostic models for prediction of survival and major complications following surgical resection of renal cell carcinoma with suprarenal caval tumor thrombus. Urol Oncol. (2015) 33(9):388 e1–9. doi: 10.1016/j.juroleonc.2015.04.010

7. Meehan B, Appu S, St Croix B, Rak-Poznanska K, Klotz L, Rak J. Age-related properties of the tumour vasculature in renal cell carcinoma. BJU Int. (2011) 107(3):416–24. doi: 10.1111/j.1464-410X.2010.09569.x

8. Martinez-Salamanca JJ, Linarees E, Gonzalez J, Bertini R, Carballido JA, Chroomeck T, et al. Lessons learned from the international renal cell carcinoma-venous thrombus consortium (Ircc-Vtc). Curr Urol Rep. (2014) 15(3):404. doi: 10.1007/s11934-014-0404-7

9. Chen Z, Yang F, Ge L, Qiu M, Liu Z, Liu Y, et al. Outcomes of renal cell carcinoma with associated venous tumor thrombus: experience from a large cohort and short time span in a single center. BMC Cancer. (2021) 21(1):766. doi: 10.1186/s12885-021-08508-x

10. Zhang Y, Tian X, Bi H, Hong P, Liu Z, Yan Y, et al. Oncologic outcomes of renal cell carcinoma patients undergoing radical nephrectomy and venous thrombectomy: prospective follow-up from a single center. J Urol. (2022) 2022:9191659. doi: 10.1155/2022/9191659

11. Shao P, Li J, Qiu C, Lv Q, Ju X, Li P, et al. Laparoscopic radical nephrectomy and inferior vena cava thrombectomy in the treatment of renal cell carcinoma. Eur Urol. (2015) 68(1):115–22. doi: 10.1016/j.eururo.2014.12.011

12. Reese AC, Whitson JM, Meng MV. Natural history of untreated renal cell carcinoma with venous tumor thrombus. Urol Oncol. (2013) 31(7):1305–9. doi: 10.1016/j.juroleonc.2011.12.006

13. Chen X, Li S, Xu Z, Wang K, Fu D, Liu Q, et al. Clinical and oncological outcomes in Chinese patients with renal cell carcinoma and venous tumor thrombus extension: single-center experience. World J Surg Oncol. (2015) 13:14. doi: 10.1186/s12957-015-0448-2

14. Hao A, Wiggins C, Lauer RC. Survival outcomes for advanced kidney cancer patients in the era of targeted therapies. Ann Transl Med. (2018) 6(9):165. doi: 10.21037/atm.2018.04.44

15. Labbate C, Hatogai K, Wernitz R, Stadler WM, Steinberg GD, Eggener S, et al. Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy. J Immunother Cancer. (2019) 7(1):66. doi: 10.1186/s40425-019-0564-8

16. Edge SB, Compton CC. The American joint committee on cancer: the 7th edition of the aJCC cancer staging manual and the future of Tnm. Ann Surg Oncol. (2010) 17(6):1471–4. doi: 10.1245/s10434-010-0985-4

17. Delahunt B, Eble JN, Samarutunga H, Thunders M, Yaxley JW, Egevad L. Staging of renal cell carcinoma: current progress and potential advances. Pathology. (2021) 53(1):120–8. doi: 10.1016/j.pathol.2020.08.007

18. Jiang W, Shou J, Shi H, Wen L, Zhang H, Zheng S, et al. Impact of primary tumor size on prognosis in patients with metastatic renal cell carcinoma receiving cytoreductive nephrectomy: a population study of a Chinese center and the us seer database. Technol Cancer Res Treat. (2021) 20: 15330338211019507. doi: 10.1177/15330338211019507

19. Kauhash D, Linder BJ, Thompson RH, Eisenberg MS, Lohse CM, Cheville JC, et al. The impact of histology on clinicopathologic outcomes for patients with renal cell carcinoma and venous tumor thrombus: a matched cohort analysis. Urology. (2013) 82(1):136–41. doi: 10.1016/j.urology.2013.02.034

20. Gu L, Wang Z, Chen L, Ma X, Li H, Nie W, et al. A proposal of post-operative nomogram for overall survival in patients with renal cell carcinoma and venous tumor thrombus. J Surg Oncol. (2017) 115(7):905–12. doi: 10.1002/jso.24575

21. Kohler T, Colla Ruvolo C, Stolzenbach LF, Wenzel M, Tian Z, Larcher A, et al. Tumor stage and substage predict cancer-specific mortality after nephrectomy for nonmetastatic renal cancer: histological subtype-specific validation. Eur Urol Focus. (2022) 8(1):182–90. doi: 10.1016/j.euf.2021.02.009

22. Delahunt B, Eble JN, Egevad L, Samarutunga H. Grading of renal cell carcinoma. Histopathology. (2019) 74(1):1–17. doi: 10.1111/his.13735

23. Srivastava A, Rivera-Núñez Z, Kim S, Sterling J, Farber NJ, Radadia KD, et al. Impact of pathologic lymph node-positive renal cell carcinoma on survival in patients without metastasis: evidence in support of expanding the definition of stage IV kidney cancer. Cancer. (2020) 126(13):2991–3001. doi: 10.1002/cncr.33912

24. John NT, Blum KA, Hakimi AA. Role of lymph node dissection in renal cell cancer. Urol Oncol. (2019) 37(3):187–92. doi: 10.1016/j.juroleonc.2018.03.006

25. Tilki D, Chandrasekar T, Capitanio U, Ciancio G, Daneshmand S, Gonttero P, et al. Impact of lymph node dissection at the time of radical nephrectomy with tumor thrombectomy on oncological outcomes: results from the international renal cell carcinoma-venous thrombus consortium (Ircc-Vtc). Urol Oncol. (2018) 36(2):79 e1–79 e17. doi: 10.1016/j.juroleonc.2017.10.008

26. Lenis AT, Burton CS, Golla V, Pooli A, Faiena I, Johnson DC, et al. Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma and venous thrombus: trends and effect on overall survival. Urol Oncol. (2019) 37(9):577 e9–16. doi: 10.1016/j.juroleonc.2018.03.006

27. Mejean A, Ravaud A, Thezenas S, Colas S, Beauval JR, Bensahel K, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med. (2018) 379(5):417–27. doi: 10.1056/NEJMoa1803675

28. Gu L, Li H, Chen L, Li X, Wang B, Huang Q, et al. Postoperative adjuvant sorafenib or sunitinib for nonmetastatic renal cell carcinoma with venous tumor thrombus: a prospective cohort study. Transl Oncol. (2017) 10(6):949–55. doi: 10.1016/j.tranon.2017.09.009

29. Yoshida K, Hata K, Iizuka J, Kondo T, Ishihara H, Ishida H, et al. Impact of venous invasion of tumor thrombus in renal cell carcinoma-venous thrombus consortium (Ircc-Vtc). Urol Oncol. (2019) 37(9):577 e9–16. doi: 10.1016/j.juroleonc.2018.03.006

30. Gu L, Li H, Chen L, Li X, Wang B, Huang Q, et al. Postoperative adjuvant sorafenib or sunitinib for nonmetastatic renal cell carcinoma with venous tumor thrombus: a prospective cohort study. Transl Oncol. (2017) 10(6):949–55. doi: 10.1016/j.tranon.2017.09.009

31. Yoshida K, Hata K, Iizuka J, Kondo T, Ishihara H, Ishida H, et al. Immune checkpoint inhibitor combination therapy for renal cell carcinomas with concomitant inferior vena cava thrombosis. In Vivo. (2022) 36(2):1630–4. doi: 10.21873/invivo.12798

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Yang and Fu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.